316 related articles for article (PubMed ID: 23271972)
21. Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF.
Chau CM; Zhang XY; McMahon SB; Lieberman PM
J Virol; 2006 Jun; 80(12):5723-32. PubMed ID: 16731911
[TBL] [Abstract][Full Text] [Related]
22. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.
Sjöblom A; Nerstedt A; Jansson A; Rymo L
J Gen Virol; 1995 Nov; 76 ( Pt 11)():2669-78. PubMed ID: 7595374
[TBL] [Abstract][Full Text] [Related]
23. Conditional expression of a dominant-negative form of Epstein-Barr virus (EBV) nuclear antigen EBNALP inhibits EBV-positive lymphoblastoid cell growth.
Harada S; Saijo M
Arch Virol; 2020 Feb; 165(2):313-320. PubMed ID: 31813023
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr Virus B Cell Growth Transformation: The Nuclear Events.
Zhao B
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112815
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
26. EBNA2 and Its Coactivator EBNA-LP.
Kempkes B; Ling PD
Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
[TBL] [Abstract][Full Text] [Related]
27. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa.
Bourillot PY; Waltzer L; Sergeant A; Manet E
J Gen Virol; 1998 Feb; 79 ( Pt 2)():363-70. PubMed ID: 9472621
[TBL] [Abstract][Full Text] [Related]
29. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J
J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782
[TBL] [Abstract][Full Text] [Related]
30. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.
Polack A; Hörtnagel K; Pajic A; Christoph B; Baier B; Falk M; Mautner J; Geltinger C; Bornkamm GW; Kempkes B
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10411-6. PubMed ID: 8816814
[TBL] [Abstract][Full Text] [Related]
31. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
32. Hsp72 up-regulates Epstein-Barr virus EBNALP coactivation with EBNA2.
Peng CW; Zhao B; Chen HC; Chou ML; Lai CY; Lin SZ; Hsu HY; Kieff E
Blood; 2007 Jun; 109(12):5447-54. PubMed ID: 17341665
[TBL] [Abstract][Full Text] [Related]
33. Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus.
Chau CM; Lieberman PM
J Virol; 2004 Nov; 78(22):12308-19. PubMed ID: 15507618
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells.
Konforte D; Simard N; Paige CJ
Virology; 2008 Apr; 374(1):100-13. PubMed ID: 18222514
[TBL] [Abstract][Full Text] [Related]
35. Activated mouse Notch1 transactivates Epstein-Barr virus nuclear antigen 2-regulated viral promoters.
Höfelmayr H; Strobl LJ; Stein C; Laux G; Marschall G; Bornkamm GW; Zimber-Strobl U
J Virol; 1999 Apr; 73(4):2770-80. PubMed ID: 10074124
[TBL] [Abstract][Full Text] [Related]
36. EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.
Portal D; Zhao B; Calderwood MA; Sommermann T; Johannsen E; Kieff E
Proc Natl Acad Sci U S A; 2011 May; 108(19):7808-13. PubMed ID: 21518914
[TBL] [Abstract][Full Text] [Related]
37. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit.
Ning S; Hahn AM; Huye LE; Pagano JS
J Virol; 2003 Sep; 77(17):9359-68. PubMed ID: 12915551
[TBL] [Abstract][Full Text] [Related]
38. Four EBNA2 domains are important for EBNALP coactivation.
Peng CW; Zhao B; Kieff E
J Virol; 2004 Oct; 78(20):11439-42. PubMed ID: 15452270
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide.
Farrell CJ; Lee JM; Shin EC; Cebrat M; Cole PA; Hayward SD
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4625-30. PubMed ID: 15070768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]